Literature DB >> 34288248

Response of the authors regarding article "J point elevation in high precordial leads associated with risk of ventricular fibrillation".

Yuki Hasegawa1, Hiroshi Watanabe1, Yasuhiro Ikami1, Sou Otsuki1, Kenichi Iijima1, Nobue Yagihara1, Daisuke Izumi1, Tohru Minamino2.   

Abstract

Entities:  

Year:  2021        PMID: 34288248      PMCID: PMC8293595          DOI: 10.1111/anec.12871

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


× No keyword cloud information.

CONFLICT OF INTEREST

None declared.

AUTHOR CONTRIBUTIONS

All persons who meet authorship criteria are listed as authors, and all authors certify that they have participated sufficiently in the work to take public responsibility for the content, including participation in the concept, design, writing, or revision of the manuscript. Furthermore, each author certifies that this material or similar material has not been and will not be submitted to or published in any other publication before its appearance in the Annals of Noninvasive Electrocardiology.

ETHICS STATEMENT

This study was approved by the ethics committee of Niigata University Medical & Dental Hospital. We thank Dr. Karakus et al. for their interest in our recently published paper assessing the usefulness of electrocardiogram recordings in the high intercostal space to identify the risk of sudden death. (Hasegawa et al., 2020) In their letter to the editor, they expressed two concerns about the findings of our study. First, they suggested the need to include clinical data of modular factors including age, heart rate, electrolyte imbalance, hyperthermia, and usage of pharmacological agents on analysis for making clear the relationship between J point elevation in high precordial leads and ventricular fibrillation. These factors could influence the development of ventricular fibrillation in J wave syndrome, (Antzelevitch et al., 2017) and we agree with the importance of considering their influences. However, in our cohort, there was no patient showing abnormalities in electrolytes or body temperature. Regarding medications, as described in our paper, only two patients with Brugada syndrome received antiarrhythmic drugs, but in other ones did not have any drugs that can affect the J wave. We showed that there is no difference in the baseline heart rate in each group. Therefore, we subjected the other factors including J point elevation in the 3rd intercostal spaces, age, and sex at diagnosis to Cox proportional hazard analysis followed by stepwise forwards and backward regression modeling. We found that J point elevation in the 3rd intercostal spaces was significantly associated with the development of ventricular fibrillation in the patients with idiopathic ventricular fibrillation, as shown in the Table 1.
TABLE 1

Results of multivariate cox analysis

Hazard ratio95% CI p value
Male sex1.3000.144–11.627.815
Age0.9760.935–1.019.270
J point elevation in the 3rd intercostal space5.2751.020–27.285.047
Results of multivariate cox analysis Second, Karakus et al. pointed out the problems of the statistical measurement methods regarding the skewness in our cohort and the comparison between the three groups. We had confirmed that all of the parameters in three groups were normally distributed and used one‐way ANOVA for the comparisons.
  2 in total

Review 1.  J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge.

Authors:  Charles Antzelevitch; Gan-Xin Yan; Michael J Ackerman; Martin Borggrefe; Domenico Corrado; Jihong Guo; Ihor Gussak; Can Hasdemir; Minoru Horie; Heikki Huikuri; Changsheng Ma; Hiroshi Morita; Gi-Byoung Nam; Frederic Sacher; Wataru Shimizu; Sami Viskin; Arthur A M Wilde
Journal:  Europace       Date:  2017-04-01       Impact factor: 5.214

2.  J point elevation in high precordial leads associated with risk of ventricular fibrillation.

Authors:  Yuki Hasegawa; Hiroshi Watanabe; Yasuhiro Ikami; Sou Otsuki; Kenichi Iijima; Nobue Yagihara; Daisuke Izumi; Tohru Minamino
Journal:  Ann Noninvasive Electrocardiol       Date:  2020-12-27       Impact factor: 1.468

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.